Feasibility of dried blood spot collection for caffeine pharmacokinetic studies in microgravity: Insights from parabolic flight campaigns
British Journal of Clinical Pharmacology · 2026
DOI: 10.1111/bcp.16320 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Audrey Derobertmasure und 8 weiteren Autor:innen. Beteiligte Einrichtung: INSERM PARCC UMRS 970, Université Paris-Cité, Paris, France. Hauptthemen laut MEDLINE: Caffeine, Dried Blood Spot Testing, Space Flight, Drug Monitoring. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Centre National d'Etudes Spatiales, Institut National de la Santé et de la Recherche Médicale, Centre National d’Etudes Spatiales.
Abstract (Originalsprache)
Aims
Therapeutic drug monitoring for astronauts faces limitations in conventional blood sampling and sample management onboard the international space station. Here, we explore the feasibility of dried blood spot (DBS) collection during parabolic flights (PF) to overcome these constraints.
Methods
We assessed the feasibility of blood deposition on blotting paper for preanalytical aspects in a PF using synthetic blood. Subsequently, DBS sampling validation was carried out in another PF campaign. Twenty volunteers participated in a pharmacokinetic study on caffeine and its metabolite, paraxanthine, conducted during parabolic flights. After >18 h caffeine washout, coffee (115 mg), tea (30 mg) or dark chocolate (11 mg) were ingested by the participants. DBS samples were collected at baseline, during weightlessness and post‐flight. Caffeine and paraxanthine were analysed using liquid chromatography–tandem mass spectrometry (LC‐MS/MS). Genotyping for cytochrome P450‐1A2 (CYP1A2) was performed and a metabolic ratio by area under the curve for caffeine and paraxanthine (AUC PAX /AUC CAF ) for CYP1A2 was determined. A user experience survey was also conducted.
Results
Full in‐flight pharmacokinetic study was feasible in seventeen volunteers with three unable to perform the sampling due to motion sickness. Nineteen participants (twelve males and seven females) completed pharmacokinetic profiles, with repeated pharmacokinetic studies for six participants. CYP1A2 genotyping resulted in eight ultrarapid, eleven intermediate, and one poor metabolizer. Among the women, four were on oestrogen contraceptives, a known inhibitor of CYP1A2, and were considered as poor metabolizers. Expected differences in kinetic profiles, consistent with consumption habits, the ingested dose and the genotypic/phenotypic information, were observed. The mean caffeine AUC for coffee, tea and chocolate were 9419 ng.h.mL −1 (95% confidence interval [CI]: 6222–12 616, n = 10), 6917 ng.h.mL −1 (95% CI: 2729–11 105), n = 7) and 3039 ng.h.mL −1 (95% CI: 1614–4142, n = 12), respectively. The mean paraxanthine AUC were 10 566 ng.h.mL −1 (95% CI: 6242–14 890, n = 10), 4011 ng.h.mL −1 (95% CI: 2305–5716, n = 7) and 3638 ng.h.mL −1 (95% CI: 1589–40 859, n = 12), respectively. The mean metabolic ratio in oestrogen‐treated women was 0.53 (95% CI: 0.35–0.71) compared to 1.19 (95% CI: 0.99–1.33) in others. The mean metabolic ratio was 1.02 (95% CI: 0.81–1.23, n = 15) on the ground and 1.10 (95% CI: 0.70–1.41, n = 13) during the parabolic flights, with no significant difference observed between the two conditions. Overall participants were satisfied with the usability of the method.
Conclusions
DBS collection was safe, stable, feasible and well accepted in weightlessness. This method would offer valuable insights into human metabolism adaptation during long‐term spaceflight, addressing space pharmacology challenges.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- INSERM PARCC UMRS 970, Université Paris-Cité, Paris, France.
- Assistance Publique Des Hôpitaux De Paris, Hôpital Européen Georges Pompidou, Clinical Pharmacology Unit and DMU CARTE, Paris, France.
- School of Pharmacy, Faculty of Science, University of Nottingham, University Park, Nottingham, UK.
- Molecular Genetics, Pharmacogenetics, and Hormonology Unit of Bicêtre, Paris-Saclay University Hospitals, Assistance Publique-Hôpitaux de Paris, Bicêtre Hospital, Paris, France.
- Laboratory of Immunology and DMU BIOPHYGEN, Georges Pompidou European Hospital and Necker-enfants malades Hospital, AP-HP; Université Paris-Cité, INEM U1151, Paris, France.
ORCID-Profile: Audrey Derobertmasure
Förderung
- Centre National d'Etudes Spatiales
- Institut National de la Santé et de la Recherche Médicale
- Centre National d’Etudes Spatiales
Zitieren
APA
Derobertmasure, A., Toh, L. S., Verstuyft, C., Lukic, S., De Sousa Carvalho, C., Couronné, R., Beauvalet, M., Chhun, S., & Boutouyrie, P. (2026). Feasibility of dried blood spot collection for caffeine pharmacokinetic studies in microgravity: Insights from parabolic flight campaigns. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16320
Vancouver
Derobertmasure A, Toh LS, Verstuyft C, Lukic S, De Sousa Carvalho C, Couronné R, et al. Feasibility of dried blood spot collection for caffeine pharmacokinetic studies in microgravity: Insights from parabolic flight campaigns. British Journal of Clinical Pharmacology. 2026. doi:10.1111/bcp.16320
BibTeX
@article{Derobertmasure2026,
author = {Derobertmasure, Audrey and Toh, Li Shean and Verstuyft, Céline and Lukic, Srboljub and De Sousa Carvalho, Christelle and Couronné, Raphaël and Beauvalet, Marie and Chhun, Stéphanie and Boutouyrie, Pierre},
title = {Feasibility of dried blood spot collection for caffeine pharmacokinetic studies in microgravity: Insights from parabolic flight campaigns},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1111/bcp.16320}
}
EUVIMED